Please indulge Doc Gumshoe while he presents his musings on what’s going on in general in the health-care arena, and in particular, which new drugs are getting the FDA blessing and why, as well as which ones are getting the short straw. My impressions and conclusions are in some cases only loosely based on […]
Articles
The plan was for Doc Gumshoe to fix his gaze on the hype around Delta 8 as the ultimate banned cancer cure, which he will definitely get around to. But the volume of comments and queries that “Cancer: The Lay of the Land in 2018” was such that I have little choice but to […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, he […]
Let’s start with a little exercise… this is the pivotal sentiment of the latest pitch from Chris Wood in his ad for Casey’s Extraordinary Technology newsletter: “The Stock Story I’m About To Share With You Is The BIGGEST Of My Entire Career” How often, do you imagine, is something similar said in an ad for […]
Since we posted the latest stock idea from our own biotech maven Dr. KSS yesterday, I couldn’t help myself — had to take a look at the biotech pitch being made by the Money Map folks who are launching their BioScience Millionaire service. But I don’t really have any time, and God knows I ain’t […]
Comments
Any thoughts on Nektar Therapeutics drug NKTR-214 which BMS has created a partnership with the 214 drug line to test wit...